Summary of testing with in vitro assays on longitudinal series of blood samples from BSE-infected donor sheep
| Assay . | No. of positive samples/no. of samples tested (% positive samples) . | |||||
|---|---|---|---|---|---|---|
| TP1 2 mpi . | TP2 6 mpi . | TP3 10 mpi . | TP4 18 mpi . | TP5 27-28 mpi . | TP6 (terminal) 18-39 mpi . | |
| mb-PMCA | 0/9 (0%) | 4/9 (44%) | 6/8 (75%) | 8/8 (100%) | 3/3 (100%) | 9/9 (100%) |
| capture-PMCA | 0/9 (0%) | 3/9 (33%) | ND | 8/8 (100%) | 3/3 (100%) | 9/9 (100%) |
| WB IOME RT-QuIC | 0/9 (0%) | 0/9 (0%) | 3/8 (38%) | 8/8 (100%) | 3/3 (100%) | 5/9 (56%) |
| Assay . | No. of positive samples/no. of samples tested (% positive samples) . | |||||
|---|---|---|---|---|---|---|
| TP1 2 mpi . | TP2 6 mpi . | TP3 10 mpi . | TP4 18 mpi . | TP5 27-28 mpi . | TP6 (terminal) 18-39 mpi . | |
| mb-PMCA | 0/9 (0%) | 4/9 (44%) | 6/8 (75%) | 8/8 (100%) | 3/3 (100%) | 9/9 (100%) |
| capture-PMCA | 0/9 (0%) | 3/9 (33%) | ND | 8/8 (100%) | 3/3 (100%) | 9/9 (100%) |
| WB IOME RT-QuIC | 0/9 (0%) | 0/9 (0%) | 3/8 (38%) | 8/8 (100%) | 3/3 (100%) | 5/9 (56%) |
Please note time points TP1-TP5 are preclinical; clinical signs of BSE were evident only at TP6 (terminal).
ND, not determined; TP, time point.